Correspondances en Onco-Théranostic - Vol. I - n° 4 - octobre-novembre-décembre 2012
172
Réparation
dossier thématique
Accédez à la pathologie moléculaire
avec Roche, votre partenaire pour l’avenir
Porté par les valeurs d’innovation et de progrès, Roche Diagnostics s’investit chaque jour dans la recherche
et le développement pour proposer aux pathologistes le meilleur du diagnostic : une offre d’instruments
complète et une large gamme de marqueurs VENTANA®, parmi laquelle celle d’anticorps pour la détection
des instabilités microsatellitaires (MSI).
Aujourd’hui Roche va plus loin et vous ouvre les portes du diagnostic moléculaire avec la PCR et le séquençage :
grâce à ce savoir-faire de pointe et à un accompagnement au quotidien, Roche acquiert une longueur
d’avance dans l’histopathologie et se place comme le partenaire d’aujourd’hui et de demain.
Décembre 2012
AP RTD ALK Ev2.indd 1 22/11/12 09:25
cancer detection and familial predisposition: development
of international criteria for the determination of microsatel-
lite instability in colorectal cancer. Cancer Res 1998;58(22):
5248-57.
10. Shia J. Immunohistochemistry versus microsatellite
instability testing for screening colorectal cancer patients at
risk for hereditary nonpolyposis colorectal cancer syndrome.
Part I. The utility of immunohistochemistry. J Mol Diagn
2008;10(4):293-300.
11. Vasen HF, van der Meulen-de Jong AE, de Vos Tot Nederveen
Cappel WH, Oliveira J; ESMO Guidelines Working Group.
Familial colorectal cancer risk: ESMO clinical recommenda-
tions. Ann Oncol 2009;20(Suppl. 4):51-3.
12. Legolvan MP, Taliano RJ, Resnick MB. Application of mole-
cular techniques in the diagnosis, prognosis and management
of patients with colorectal cancer: a practical approach. Hum
Pathol 2012;43(8):1157-68.
13.
Hampel H, Frankel WL, Martin E et al. Feasibility of screen-
ing for Lynch syndrome among patients with colorectal cancer.
J Clin Oncol 2008;26(35):5783-8.
14. Moreira L, Balaguer F, Lindor N et al. Identification of
Lynch syndrome among patients with colorectal cancer.
JAMA 2012;308(15):1555-65.
15. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda
Guidelines for hereditary nonpolyposis colorectal cancer (Lynch
syndrome) and microsatellite instability. J Natl Cancer Inst
2004;96(4):261-8.
16. Gausachs M, Mur P, Corral J et al. MLH1 promoter hyper-
methylation in the analytical algorithm of Lynch syndrome:
a cost-effectiveness study. Eur J Hum Genet 2012;20(7):762-8.
17.
Wang G, Kuppermann M, Kim B, Phillips KA, Ladabaum
U. Influence of patient preferences on the cost-effectiveness
of screening for Lynch syndrome. J Oncol Pract 2012;8(3
Suppl.):e24s-30s.
18. Ramsey SD, Clarke L, Etzioni R et al. Cost-effectiveness of
microsatellite instability screening as a method for detecting
hereditary nonpolyposis colorectal cancer. Ann Intern Med
2001;135(8 Pt 1):577-88.
19.
Ladabaum U, Wang G, Terdiman J et al. Strategies to iden-
tify the Lynch syndrome among patients with colorectal cancer:
a cost-effectiveness analysis. Ann Intern Med 2011;155(2):
69-79.
20.
Kastrinos F, Syngal S. Screening patients with colorectal
cancer for Lynch syndrome: what are we waiting for? J Clin
Oncol 2012;30(10):1024-7.
21.
Al-Tassan N, Chmiel NH, Maynard J et al. Inherited variants
of MYH associated with somatic G:CT:A mutations in colorec-
tal tumors. Nat Genet 2002;30(2):227-32.
22.
Grover S, Kastrinos F, Steyerberg EW et al. Prevalence and
phenotypes of APC and MUTYH mutations in patients with
multiple colorectal adenomas. JAMA 2012;308(5):485-92.
23.
Timmermann B, Kerick M, Roehr C et al. Somatic mutation
profiles of MSI and MSS colorectal cancer identified by whole
exome next generation sequencing and bioinformatics ana-
lysis. PLoS One 2010;5(12):e15661.
24. Parc Y, Gueroult S, Mourra N et al. Prognostic significance of
microsatellite instability determined by immunohistochemical
staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer.
Gut 2004;53(3):371-5.
25. Popat S, Hubner R, Houlston RS. Systematic review of
microsatellite instability and colorectal cancer prognosis.
J Clin Oncol 2005;23(3):609-18.
26. Ishikawa T, Fujita T, Suzuki Y et al. Tumor-specific immu-
nological recognition of frameshift-mutated peptides in
colon cancer with microsatellite instability. Cancer Res
2003;63(17):5564-72.
27. Bauer K, Nelius N, Reuschenbach M et al. T cell responses
against microsatellite instability-induced frameshift peptides
and influence of regulatory T cells in colorectal cancer. Cancer
Immunol Immunother 2012. [Epub ahead of print]
28. Guidoboni M, Gafà R, Viel A et al. Microsatellite instability
and high content of activated cytotoxic lymphocytes identify
colon cancer patients with a favorable prognosis. Am J Pathol
2001;159(1):297-304.
29.
Román R, Verdú M, Calvo M et al. Microsatellite instability
of the colorectal carcinoma can be predicted in the conven-
tional pathologic examination. A prospective multicentric
study and the statistical analysis of 615 cases consolidate
our previously proposed logistic regression model. Virchows
Arch 2010;456(5):533-41.
30. Jass JR. Lymphocytic infiltration and survival in rectal
cancer. J Clin Pathol 1986;39(6):585-9.
31. Pagès F, Berger A, Camus M et al. Effector memory T cells,
early metastasis, and survival in colorectal cancer. N Engl J
Med 2005;353(25):2654-66.
32. Allard MA, Bachet JB, Beauchet A et al. Linear quantification
of lymphoid infiltration of the tumor margin: a reproducible
method, developed with colorectal cancer tissues, for assessing
a highly variable prognostic factor. Diagn Pathol 2012;7(1):156.
33. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-
instability status as a predictor of benefit from fluorouracil-
based adjuvant chemotherapy for colon cancer. N Engl J Med
2003;349(3):247-57.
34. Sargent DJ, Marsoni S, Monges G et al. Defective mis-
match repair as a predictive marker for lack of efficacy of
fluoro uracil-based adjuvant therapy in colon cancer. J Clin
Oncol 2010;28(20):3219-26.
35. Zaanan A, Fléjou JF, Emile JF et al. Defective mismatch
repair status as a prognostic biomarker of disease-free survival
in stage III colon cancer patients treated with adjuvant FOLFOX
chemotherapy. Clin Cancer Res 2011;17(23):7470-8.
Références
Abonnez-vous en ligne !
Bulletin d’abonnement
disponible page 165
www.edimark.fr